Related Experiment Video
Updated: Aug 17, 2026
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
A new cancer diagnostic system based on a CDK profiling technology
Hideki Ishihara1, Tomokazu Yoshida, Yuko Kawasaki
1Central Research Laboratories, Sysmex Corporation, 4-4-4, Takatsukadai, Nishi-ku, Kobe 651-2271, Japan. Hideki_Ishihara@sysmex.co.jp
Abstract:
A series of molecular pathological investigations of the molecules that stimulate the cyclin dependent kinases (CDK1, 2, 4, and 6) have led to enormous accumulation of knowledge of the clinical significance of these molecules for cancer diagnosis. However, the molecules have yet to be applied to clinical cancer diagnosis, as there is no available technology for application of the knowledge in a clinical setting. We hypothesized that the direct measurement of CDK activities and expressions (CDK profiling) might produce clinically relevant values for the diagnosis. This study investigated the clinical relevance of CDK profiling in gastrointestinal carcinoma tissues by using originally developed expression and activity analysis methods. We have established novel methods and an apparatus for analyzing the expression and activities of the CDK molecules in lysate of tumor tissue in a clinical setting, and examined 30 surgically dissected gastrointestinal carcinomas and corresponding normal mucosal specimens. We demonstrate here that remarkably elevated CDK2 activity is evident in more than 70% of carcinoma tissues. Moreover, a G1-CDK activity profiling accurately mirrored the differences in proliferation between tumor and normal colonic tissues. Our results suggest that CDK profiling is a potent molecular-clinical approach to complement the conventional pathological diagnosis, and to further assist in the individualized medications.
Insights
CDK profiling, a novel method measuring cyclin-dependent kinase (CDK) activity and expression, shows promise for gastrointestinal cancer diagnosis. Elevated CDK2 activity in tumors suggests its potential as a diagnostic biomarker.
Area of Science:
- Molecular pathology
- Oncology
- Biomarker discovery
Background:
- Cyclin-dependent kinases (CDKs) are crucial for cell cycle regulation and implicated in cancer.
- Despite extensive knowledge of CDK roles in cancer, clinical diagnostic applications are limited by a lack of suitable technology.
- CDK profiling offers a potential solution for translating molecular insights into clinical practice.
Purpose of the Study:
- To investigate the clinical relevance of CDK profiling in gastrointestinal carcinoma tissues.
- To establish novel methods and apparatus for analyzing CDK expression and activity in tumor tissue lysates.
- To assess the diagnostic potential of CDK profiling for gastrointestinal cancers.
Main Methods:
- Development of novel methods and apparatus for CDK expression and activity analysis.
- Analysis of CDK profiles in 30 surgically dissected gastrointestinal carcinomas and matched normal mucosal specimens.
- Comparison of CDK activity and expression patterns between tumor and normal tissues.
Main Results:
- Elevated CDK2 activity was observed in over 70% of gastrointestinal carcinoma tissues.
- G1-CDK activity profiling accurately reflected proliferation differences between tumor and normal colonic tissues.
- The developed methods demonstrated feasibility for clinical settings.
Conclusions:
- CDK profiling is a potent molecular-clinical approach complementing conventional pathological diagnosis.
- CDK profiling can aid in the individualized treatment of gastrointestinal cancers.
- Further validation of CDK profiling may lead to improved cancer diagnostics and personalized medicine.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:17Karyotyping